JM4
JM4 has been studied in 1 paper since 2021: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Jan 27, 2021: “Erythropoietin-derived peptide treatment reduced neurological deficit and neuropathological changes in a mouse model of tauopathy”.
- 1 lab in 1 country
- Funders: National Institute of Neurological Disorders and Stroke and 3 more
- Animals1
What did studies of JM4 find?
5Studies of JM4 measured 5 outcomes; the most studied are phosphorylated tau aggregation (1 study), neuronal loss (1) and memory impairment (1).
Phosphorylated tau aggregation
downin mice1
1 study
Phosphorylated tau aggregation
downin mice1
JM4 decreases phosphorylated tau aggregation in mice.
“reductions in neuronal loss, phosphorylated tau aggregation, and microglial activation in the PS19 mouse brain”
AnimalsPS19 tauopathy mouse model19'mer cyclic peptidebrainfemales
Alzheimer's research & therapy
Neuronal loss
downin mice1
1 study
Neuronal loss
downin mice1
JM4 decreases neuronal loss in mice.
“reductions in neuronal loss, phosphorylated tau aggregation, and microglial activation in the PS19 mouse brain”
AnimalsPS19 tauopathy mouse model19'mer cyclic peptidebrainfemales
Alzheimer's research & therapy
Memory impairment
downin mice1
1 study
Memory impairment
downin mice1
JM4 decreases memory impairment in mice.
“rescued memory impairment”
AnimalsPS19 tauopathy mouse model19'mer cyclic peptidefemales
Alzheimer's research & therapy
Lifespan
upin mice1
1 study
Lifespan
upin mice1
JM4 extends lifespan in mice.
“prolonged lifespan”
AnimalsPS19 tauopathy mouse model19'mer cyclic peptidefemales
Alzheimer's research & therapy
Neurological deficit
downin mice1
1 study
Neurological deficit
downin mice1
JM4 decreases neurological deficit in mice.
“JM4 treatment of PS19 mice initiated before disease onset reduced neurological deficit”
AnimalsPS19 tauopathy mouse model19'mer cyclic peptidebrainfemales
Alzheimer's research & therapy